Clinical observation of tocilizumab in patients with refractory active rheumatoid arthritis
10.3760/cma.j.issn.1007-7480.2015.07.005
- VernacularTitle:托珠单抗注射液治疗32例难治性活动性类风湿关节炎的临床观察
- Author:
Ke SHANG
;
Hui PI
;
Youlian WANG
- Publication Type:Journal Article
- Keywords:
Interleukin-6;
Antibodies,monoclonal;
Arthritis,rheumatoid;
Treatment outcome
- From:
Chinese Journal of Rheumatology
2015;(7):451-454
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the efficacy and safety of tocilizumab in combination with disease-modifying anti-rheumatoid drugs (DMARDs) for the treatment of rheumatoid arthritis (RA) patients with moderate to severe activity and inadequate response to DMARDs. Methods Thirty-two RA patients with inadequate response to DMARDs were treated with tocilizumab along with stable dose of DMARDs for 12 weeks, adverse reactions were recorded, clinical laboratory and physiological indices were recorded 4, 8, and 12 weeks after treatment. The routine blood, liver and kidney function tests, morning stiffness, rest pain, tender joint count, swollen joint count, overall evaluation of the patient and physician to disease and health assessment questionnaire, blood sedimentation, C-reactive protein (CRP), Disease activity score 28 (DAS28), simplified disease activity index (SDAI) score, clinical disease activity index (CDAI). Repetitive measure analysis of variance wase used for statistical analysis. Results The clinical laboratory indices and DAS28, SDAI, CDAI scores observed in all of the patients were significantly improved (P<0.05). After 8 and 12 weeks of treatment, disease activity was further improved with statistical significance (P<0.05). The levels of IL-6 were downregulated obvious compared with before [(26±14) pg/ml vs (76±39) pg/ml, t=-6.925, P<0.01], and no obvious adverse reactions were observed. Conclusion Tocilizumab can quickly improve the symptoms and the control disease activity of refractory active RA within a few weeks.
